Spectrum Pharmaceuticals Announces Promising Clinical Data for ZEVALIN(R) and ... MarketWatch (press release) A Phase 2 investigator-sponsored study in patients with stage III/IV CD20+ DLBCL (Abstract # 6633) found that short-duration therapy consisting of rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone given every 14 days (RCHOP-14) ... |
